Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 24 | 2026 | 2037 | 2.590 |
Why?
|
| Community Health Workers | 5 | 2026 | 80 | 1.410 |
Why?
|
| Malawi | 21 | 2026 | 338 | 1.190 |
Why?
|
| Contact Tracing | 4 | 2026 | 58 | 1.040 |
Why?
|
| Mass Screening | 6 | 2026 | 814 | 1.000 |
Why?
|
| Health Personnel | 10 | 2026 | 549 | 0.930 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2026 | 500 | 0.760 |
Why?
|
| Drug Resistance, Viral | 4 | 2026 | 57 | 0.730 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2026 | 45 | 0.650 |
Why?
|
| Anti-HIV Agents | 6 | 2025 | 353 | 0.650 |
Why?
|
| Anti-Retroviral Agents | 3 | 2018 | 154 | 0.630 |
Why?
|
| HIV-1 | 3 | 2026 | 484 | 0.530 |
Why?
|
| Pyridones | 4 | 2026 | 148 | 0.510 |
Why?
|
| Oxazines | 3 | 2026 | 32 | 0.500 |
Why?
|
| Dependovirus | 3 | 2022 | 161 | 0.450 |
Why?
|
| Piperazines | 3 | 2026 | 268 | 0.440 |
Why?
|
| Counseling | 4 | 2020 | 237 | 0.410 |
Why?
|
| Feasibility Studies | 2 | 2026 | 812 | 0.360 |
Why?
|
| Hypoglycemic Agents | 2 | 2025 | 478 | 0.330 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2020 | 499 | 0.330 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2020 | 261 | 0.290 |
Why?
|
| Tuberculosis | 3 | 2020 | 554 | 0.270 |
Why?
|
| Burnout, Professional | 2 | 2019 | 133 | 0.250 |
Why?
|
| Medication Adherence | 3 | 2020 | 335 | 0.240 |
Why?
|
| Adult | 15 | 2026 | 31179 | 0.240 |
Why?
|
| HIV Integrase | 1 | 2024 | 3 | 0.220 |
Why?
|
| Cluster Analysis | 1 | 2026 | 412 | 0.220 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2024 | 15 | 0.220 |
Why?
|
| Female | 21 | 2026 | 70388 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2025 | 1438 | 0.210 |
Why?
|
| Humans | 33 | 2026 | 130483 | 0.210 |
Why?
|
| Male | 17 | 2026 | 64488 | 0.210 |
Why?
|
| Tropism | 2 | 2020 | 9 | 0.200 |
Why?
|
| Qualitative Research | 2 | 2025 | 698 | 0.200 |
Why?
|
| Quality of Health Care | 2 | 2018 | 409 | 0.200 |
Why?
|
| Capsid | 2 | 2020 | 95 | 0.200 |
Why?
|
| Capsid Proteins | 2 | 2020 | 148 | 0.190 |
Why?
|
| HIV | 1 | 2023 | 176 | 0.190 |
Why?
|
| Thyroid Neoplasms | 1 | 2025 | 249 | 0.190 |
Why?
|
| Child | 11 | 2026 | 26101 | 0.180 |
Why?
|
| AIDS Serodiagnosis | 2 | 2019 | 52 | 0.170 |
Why?
|
| Research Personnel | 1 | 2023 | 141 | 0.170 |
Why?
|
| Adolescent | 9 | 2026 | 20737 | 0.160 |
Why?
|
| Learning | 1 | 2024 | 370 | 0.160 |
Why?
|
| Breast Diseases | 1 | 2020 | 36 | 0.160 |
Why?
|
| Audiovisual Aids | 1 | 2020 | 22 | 0.160 |
Why?
|
| Gene Editing | 1 | 2022 | 235 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2026 | 916 | 0.150 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2019 | 23 | 0.150 |
Why?
|
| Viral Load | 3 | 2026 | 406 | 0.150 |
Why?
|
| Mammography | 1 | 2020 | 123 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2026 | 1060 | 0.150 |
Why?
|
| Calcinosis | 1 | 2020 | 180 | 0.140 |
Why?
|
| Syphilis | 1 | 2019 | 95 | 0.140 |
Why?
|
| Blood-Brain Barrier | 1 | 2019 | 154 | 0.140 |
Why?
|
| Early Diagnosis | 1 | 2018 | 189 | 0.130 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2017 | 39 | 0.130 |
Why?
|
| Child, Preschool | 5 | 2026 | 14945 | 0.130 |
Why?
|
| Health Services Research | 1 | 2018 | 179 | 0.130 |
Why?
|
| Young Adult | 4 | 2026 | 10010 | 0.130 |
Why?
|
| Family Characteristics | 1 | 2017 | 97 | 0.120 |
Why?
|
| Community Health Services | 1 | 2017 | 87 | 0.120 |
Why?
|
| Infection Control | 1 | 2017 | 162 | 0.120 |
Why?
|
| Family | 1 | 2018 | 585 | 0.110 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2025 | 33 | 0.110 |
Why?
|
| Cross Infection | 1 | 2017 | 332 | 0.110 |
Why?
|
| Antitubercular Agents | 1 | 2016 | 269 | 0.100 |
Why?
|
| Infant | 3 | 2026 | 13234 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 233 | 0.100 |
Why?
|
| Self Report | 3 | 2020 | 555 | 0.090 |
Why?
|
| Genetic Therapy | 3 | 2022 | 718 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 2105 | 0.090 |
Why?
|
| Middle Aged | 7 | 2026 | 28438 | 0.080 |
Why?
|
| Treatment Adherence and Compliance | 2 | 2020 | 10 | 0.080 |
Why?
|
| Transduction, Genetic | 2 | 2022 | 277 | 0.080 |
Why?
|
| Gene Amplification | 1 | 2009 | 220 | 0.070 |
Why?
|
| Pediatrics | 1 | 2018 | 1242 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2026 | 3806 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2025 | 17550 | 0.070 |
Why?
|
| Genetic Vectors | 2 | 2022 | 899 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 1266 | 0.060 |
Why?
|
| Attitude of Health Personnel | 2 | 2025 | 703 | 0.060 |
Why?
|
| Prevalence | 2 | 2026 | 2699 | 0.060 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 694 | 0.060 |
Why?
|
| Pregnancy | 4 | 2020 | 7407 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 1297 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2009 | 621 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2026 | 349 | 0.060 |
Why?
|
| Sulfonylurea Compounds | 1 | 2024 | 21 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2024 | 231 | 0.050 |
Why?
|
| Ethics Committees, Research | 1 | 2024 | 29 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 1376 | 0.050 |
Why?
|
| Developing Countries | 1 | 2025 | 301 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2026 | 4021 | 0.050 |
Why?
|
| Integrases | 1 | 2023 | 157 | 0.050 |
Why?
|
| Macaca | 1 | 2022 | 59 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 444 | 0.050 |
Why?
|
| Melanoma | 1 | 2009 | 924 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12843 | 0.040 |
Why?
|
| Capacity Building | 1 | 2021 | 26 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 900 | 0.040 |
Why?
|
| Aged | 3 | 2025 | 20918 | 0.040 |
Why?
|
| Tanzania | 1 | 2020 | 66 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2020 | 120 | 0.040 |
Why?
|
| Type D Personality | 1 | 2019 | 3 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 150 | 0.040 |
Why?
|
| Marital Status | 1 | 2019 | 33 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 298 | 0.040 |
Why?
|
| Swine | 1 | 2022 | 1185 | 0.040 |
Why?
|
| Genotype | 1 | 2025 | 2596 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2020 | 235 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2019 | 80 | 0.040 |
Why?
|
| Virion | 1 | 2019 | 116 | 0.040 |
Why?
|
| Job Satisfaction | 1 | 2019 | 100 | 0.040 |
Why?
|
| Cryoelectron Microscopy | 1 | 2020 | 242 | 0.040 |
Why?
|
| Family Health | 1 | 2019 | 242 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 130 | 0.030 |
Why?
|
| Depersonalization | 1 | 2018 | 10 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2023 | 1227 | 0.030 |
Why?
|
| Video Recording | 1 | 2019 | 207 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2019 | 276 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 522 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2019 | 805 | 0.030 |
Why?
|
| Prenatal Care | 1 | 2019 | 346 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 760 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2019 | 615 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 679 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 2566 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1343 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 1660 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 564 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 1880 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 832 | 0.030 |
Why?
|
| Coinfection | 1 | 2016 | 187 | 0.030 |
Why?
|
| Mice | 2 | 2022 | 18243 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 1169 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 505 | 0.030 |
Why?
|
| Public Health | 1 | 2016 | 272 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1076 | 0.020 |
Why?
|
| Risk Factors | 2 | 2019 | 10953 | 0.020 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 427 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2016 | 1215 | 0.020 |
Why?
|
| Mutation | 1 | 2024 | 6119 | 0.020 |
Why?
|
| Depression | 1 | 2019 | 1317 | 0.020 |
Why?
|
| Animals | 2 | 2022 | 33862 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2838 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2009 | 62 | 0.020 |
Why?
|
| Genes, ras | 1 | 2009 | 97 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 6809 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2009 | 191 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 436 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 2598 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2009 | 734 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2009 | 219 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 789 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 3164 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2016 | 3679 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 5176 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 6200 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8518 | 0.010 |
Why?
|